HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (3- (4- (3- (glucopyranosyloxy)- 5- isopropyl- 1H- pyrazol- 4- ylmethyl)- 3- methylphenoxy)propylamino)propionamide

structure in first source

Also Known As:

3-(3-(4-(3-(beta-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl)-3-methylphenoxy)propylamino)propionamide; KGA-2727

Networked: 3 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - 3-(3-(4-(3-(glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl)-3-methylphenoxy)propylamino)propionamide: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - 3-(3-(4-(3-(glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl)-3-methylphenoxy)propylamino)propionamide: 3

Experts

1.	Hirose, Masamichi: 1 article (01/2020)
2.	Ibi, Miho: 1 article (01/2020)
3.	Ishida, Nanae: 1 article (01/2020)
4.	Matsushita, Naoko: 1 article (01/2020)
5.	Morino, Yoshihiro: 1 article (01/2020)
6.	Saito, Maki: 1 article (01/2020)
7.	Sawa, Yohei: 1 article (01/2020)
8.	Taira, Eiichi: 1 article (01/2020)
9.	Fushimi, Nobuhiko: 1 article (08/2012)
10.	Isaji, Masayuki: 1 article (08/2012)

Related Diseases

1.	Ventricular Remodeling 01/01/2020 - "Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice." 01/01/2020 - "These results suggest that KGA-2727 pretreatment protects against MI-induced left ventricular remodeling through SGLT1 blockade and that it may become a new pharmacological therapy for ischemia-induced cardiomyopathy."
2.	Myocardial Infarction 01/01/2020 - "We examined the effects of KGA-2727, a selective SGLT1 inhibitor, on myocardial infarction (MI)-induced ischemic cardiomyopathy. " 01/01/2020 - "Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice."
3.	Hyperglycemia 08/01/2012 - "In the oral glucose tolerance test with streptozotocin-induced diabetic rats, KGA-2727 attenuated the elevation of plasma glucose after glucose loading, indicating that KGA-2727 improved postprandial hyperglycemia. "
4.	Heart Failure 01/01/2020 - "Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice."
5.	Cardiomyopathies (Cardiomyopathy) 01/01/2020 - "We examined the effects of KGA-2727, a selective SGLT1 inhibitor, on myocardial infarction (MI)-induced ischemic cardiomyopathy. " 01/01/2020 - "These results suggest that KGA-2727 pretreatment protects against MI-induced left ventricular remodeling through SGLT1 blockade and that it may become a new pharmacological therapy for ischemia-induced cardiomyopathy."

Related Drugs and Biologics

1.	Streptozocin (Streptozotocin)
2.	Glucose (Dextrose)
3.	salicylhydroxamic acid (SHAM)
4.	mizagliflozin

Related Therapies and Procedures

1.	Therapeutics